Trials of cell therapy are reporting data on remissions and relapses in severe refractory autoimmune diseases. The therapy appears to have led to long-term remissions in some patients with certain types of lymphoma, although the specific outcomes and patient populations vary across different reports. The effectiveness of the therapy for other conditions, such as myeloma and vasculitis, is also being studied, with some reports indicating durable responses.